Calico's relationship with AbbVie is essential and aims to develop therapies that improve the lives of people with age-related diseases, said Art Levinson, founder of Calico. This partnership aims to strengthen the efforts of Calico scientifically to understand aging and thus advance their clinical trials to find therapies that can help patients worldwide.

Under the agreement, Calico will be responsible for establishing a research center focused on drug discovery and development in the Bay Area of San Francisco. AbbVie provide support for clinical trials and help develop new drugs to marketing.

The two companies will each contribute an initial sum of $ 250 million and could eventually provide up to 500 million more to fund the association.

Google and other futuristic invests in activities outside its core business on the Internet, ranging from driverless cars to a sharing program for drones. Calico (which stands for California Life Company) was formally established in September 2013, and that same month, the company was featured in a cover story of Time magazine under the headline "Can Google Solve death?"

Calico currently has only six employees listed on their website, but the company says it plans to start building a large team of scientists and research staff in the Bay Area of San Francisco.

Calico is not the first effort to find a way to reverse the aging clock. Earlier this year, the scientist Craig Venter genome received $ 70 million for startup, "Human Longevity" (human longevity), which aims to build a comprehensive database of genetic data to address related diseases aging.

Photography: Own work Sento Segarra